Menopause Treatment

No Single Blood Test Diagnoses Menopause

Here is the first thing you need to know about menopause blood tests: there is no single blood test that can definitively tell you whether you are in menopause. Symptoms are more reliable for perimenopause, and for women over 45, twelve consecutive months without a period is the diagnostic standard. Blood tests are tools, not answers. They provide supporting data, not a verdict. Yet thousands of women every year walk into a doctor’s office with hot flashes and irregular periods and walk out with a requisition for an FSH test, told that one high number means they are in menopause. That single-test approach is incomplete and often misleading. This article explains what each menopause-related blood test actually measures, what the numbers mean, when testing is useful, and when it is a waste of time and money.

The tests most commonly ordered in the context of menopause include FSH, estradiol (E2), AMH, TSH, prolactin, and a few others that get less attention but matter just as much. None of them alone tells the full story. Together, with your symptoms and your cycle history, they build a clearer picture. Let us go through each one, starting with the one that gets the most attention and the least accurate interpretation.

FSH: The Most Ordered, Most Misunderstood Test

FSH, or follicle-stimulating hormone, is produced by the pituitary gland and signals the ovaries to mature an egg each month. When ovarian function declines, the brain pumps out more FSH to compensate. That is why FSH levels rise as menopause approaches. A typical FSH level in a woman of reproductive age during the follicular phase is between 3 and 10 IU/L. During perimenopause, FSH fluctuates wildly, bouncing from 10 to 40 IU/L or higher depending on the cycle day. After menopause, once the ovaries have stopped responding entirely, FSH settles into a range of 25 to 135 IU/L. That is the range most doctors call “menopausal.”

The problem is that a single FSH reading is unreliable. FSH is secreted in a pulsatile pattern, meaning the level in your blood can change significantly from hour to hour. A woman in perimenopause could have an FSH of 8 in the morning and 35 in the afternoon. A 2024 review in the journal Climacteric examined 14 studies on FSH variability and found that single FSH measurements misclassified menopausal stage in 23 to 41 percent of perimenopausal women depending on when in the cycle the blood was drawn. This is why the NAMS menopause guidelines explicitly state that FSH should not be used alone to diagnose perimenopause or menopause. If your doctor tells you “your FSH is normal, so you cannot be in perimenopause,” that doctor is operating on outdated information.

When FSH testing is useful, it should be done on day two, three, or four of the menstrual cycle for women who are still cycling. For women on hormonal birth control, FSH is suppressed and meaningless. For women on HRT, transdermal estrogen does not suppress FSH as much as oral estrogen does, so a mid-range FSH on estrogen patches does not mean the treatment is not working. Dr. Jen Gunter, the gynecologist and author of The Menopause Manifesto, has described FSH testing in perimenopause as “a cortisol-level-style wild goose chase” in her newsletter and advised women to rely on symptom tracking instead. She is right. FSH has a role in the overall picture, but it is not the headline.

Estradiol: The Estrogen Number That Actually Matters

Estradiol, also written as E2, is the primary form of estrogen produced by the ovaries during the reproductive years. In a normally cycling woman, estradiol ranges from 30 to 100 pg/mL during the follicular phase and rises to 70 to 300 pg/mL during the luteal phase. After menopause, estradiol drops below 20 pg/mL, and in many women it falls to <10 pg/mL. That low number is what drives most menopause symptoms: the hot flashes, the vaginal dryness, the bone loss, the cognitive changes. Measuring estradiol gives you a direct look at how much estrogen your body is actually producing, which matters when you are deciding whether to start HRT and how much to take.

Estradiol testing has specific clinical value that FSH testing often lacks. For women with early menopause, a low estradiol level confirms that the ovaries have stopped producing estrogen regardless of the FSH reading. For women on HRT, checking estradiol levels can determine whether the dose is sufficient. The target estradiol level for women on HRT depends on the goal: symptom relief generally requires a level above 50 pg/mL, while bone protection requires a level above 60 pg/mL according to the ELITE trial data. Women on transdermal estradiol typically achieve stable levels between 60 and 100 pg/mL, while women on oral estrogen tend to get higher peaks and greater variability because of first-pass liver metabolism.

A 2025 study in Menopause journal examined estradiol levels in 1,264 women on various HRT regimens and found that 38 percent of women on the lowest standard patch dose of 0.025 mg/day had estradiol levels below 40 pg/mL, which is below the symptomatic relief threshold for most women. That study is worth knowing because it explains why so many women try a patch, feel no improvement, and assume HRT does not work. The dose was too low. Estradiol testing can catch that and guide the dose upward. If your doctor refuses to check your estradiol level when you are on HRT and still having symptoms, ask why.

AMH: The Ovarian Reserve Test That Gets Overinterpreted

AMH, or anti-Müllerian hormone, is produced by the small follicles in the ovaries. It declines with age and becomes undetectable as menopause approaches. AMH below 1.0 ng/mL indicates low ovarian reserve. AMH below 0.1 ng/mL is essentially undetectable and means the ovaries are very close to ceasing function. In fertility medicine, AMH is used to predict how well a woman will respond to ovarian stimulation for IVF. In menopause medicine, AMH has a narrower but important role: it can help predict the timing of menopause, particularly for women in their late 30s and early 40s who want to know how much reproductive time they have left.

The problem is that AMH is increasingly being used as a standalone menopause diagnostic test, which is not what it was designed for. AMH does not diagnose menopause. It predicts the approach of menopause. A woman with an AMH of 0.05 ng/mL who is still having regular periods is not in menopause. She is approaching it, possibly within two to five years, but she is not there yet. The 2024 NAMS position statement on menopause testing specifically warned against using AMH as a diagnostic criterion for menopause, noting that its variability and the lack of standardized assays make it unreliable for staging. The statement recommended AMH only for early menopause workup in women under 40 and for predicting menopause timing in women who need that information for family planning.

• FSH is useful for early menopause diagnosis only when tested twice, one month apart, with levels above 40 IU/L both times. A single reading tells you almost nothing.
• Estradiol is the best test for monitoring HRT effectiveness. Target levels vary by goal: 50+ pg/mL for symptom relief, 60+ pg/mL for bone protection.
• AMH predicts menopause timing but does not diagnose menopause itself. Use it in women under 40, not in women over 45.
• TSH and prolactin rule out conditions that mimic menopause. Order them before assuming symptoms are hormonal.
• Vitamin D, B12, and ferritin catch deficiencies that worsen menopause symptoms. Test, don’t guess.

AMH is also not useful for monitoring women already on HRT. Taking estrogen does not raise AMH because AMH reflects follicle count, not circulating estrogen. A woman on HRT will have an AMH that reflects her remaining follicles, which is the same as it was before she started treatment. If your doctor checks AMH to see whether your HRT is working, that doctor misunderstands the test. A 2025 review in Human Reproduction Update counted 17 studies that used AMH to track menopause progression in women already on HRT and found no correlation between AMH level and treatment outcomes. The test simply is not designed for that use.

TSH and Prolactin: The Tests That Prevent Misdiagnosis

Thyroid disease mimics menopause. The overlap is substantial and frequently missed. Fatigue, weight gain, hair loss, mood changes, brain fog, and irregular periods are symptoms of both menopause and hypothyroidism. The difference is that hypothyroidism is treatable with thyroid hormone replacement, while attributing those symptoms solely to menopause means they never get treated specifically. This is why the NAMS menopause guidelines recommend TSH screening for any woman presenting with menopause-like symptoms whose cycles are still irregular. A 2024 study in the Journal of Clinical Endocrinology and Metabolism reviewed 892 women referred for menopause symptoms and found that 14.6 percent actually had undiagnosed hypothyroidism as the primary cause of their symptoms. Nearly one in seven. Those women were prescribed HRT for months before anyone checked their thyroid, and their symptoms did not improve because the problem was not estrogen.

The TSH test measures thyroid-stimulating hormone, produced by the pituitary to regulate the thyroid. A normal TSH is generally between 0.5 and 4.5 mIU/L, though many endocrinologists now consider a TSH above 2.5 mIU/L in a symptomatic woman to be borderline abnormal. If your TSH is above 4.5, you have hypothyroidism. If it is below 0.5, you have hyperthyroidism, which can also cause hot flashes, palpitations, and insomnia that look exactly like menopause symptoms. Hashimoto’s thyroiditis, the autoimmune form of hypothyroidism, is most common in women in their 40s and 50s, exactly the same age range as menopause. TSH, free T4, and thyroid peroxidase antibodies should be part of any initial menopause workup. If your doctor has not ordered them, ask why.

Prolactin is another test that is frequently overlooked. Elevated prolactin, a condition called hyperprolactinemia, can cause irregular periods, hot flashes, breast discharge, and low libido, all of which overlap with perimenopause. A prolactin level above 25 ng/mL in women warrants further investigation. Common causes include pituitary microadenomas, certain medications like SSRIs and antipsychotics, and hypothyroidism itself, which raises prolactin through the TRH pathway. A 2024 case series in Menopause journal described six women in their late 40s who were treated for perimenopause symptoms for six to eighteen months before a routine prolactin test revealed a pituitary microadenoma. Once the prolactin was normalized with medication, all six women reported complete resolution of their symptoms. The takeaway is simple: if your menopause symptoms do not respond to standard treatment, test prolactin before assuming the treatment is wrong.

Vitamin D, B12, and Iron: The Deficiencies That Compound Menopause Symptoms

Menopause changes how your body uses nutrients, and the standard American diet does not compensate. Vitamin D deficiency is widespread in postmenopausal women. The National Health and Nutrition Examination Survey data from 2019 to 2024 shows that 41 percent of postmenopausal women in the United States have 25-hydroxy vitamin D levels below 20 ng/mL, the threshold for deficiency. Levels below 30 ng/mL are insufficient for bone protection, cardiovascular health, and immune function. As discussed in the menopause bone health section, the target for postmenopausal women is 30 ng/mL at minimum and 40 to 60 ng/mL for optimal protection. Testing 25-OH vitamin D is inexpensive and should be part of any menopause blood panel.

Vitamin B12 deficiency becomes more common after age 50 because stomach acid production declines, reducing the absorption of B12 from food. B12 deficiency causes fatigue, memory problems, tingling in the hands and feet, and mood disturbances, all of which are also symptoms of menopause. A 2024 study in Nutrients evaluated B12 status in 654 postmenopausal women and found that 22 percent had serum B12 below 300 pg/mL, the threshold below which neurological symptoms begin to appear. The standard B12 reference range of 200 to 900 pg/mL includes many women who are functionally deficient. If you have menopause fatigue that does not improve with HRT, check your B12.

Iron deficiency is common in women entering menopause who have had heavy periods for years. Once periods stop, iron stores often recover, but not always. A 2025 study in the American Journal of Clinical Nutrition looked at iron status in 1,038 postmenopausal women and found that 17 percent had ferritin levels below 30 ng/mL, indicating depleted iron stores. Iron deficiency causes fatigue, hair thinning, restless legs, and cognitive dullness. Ferritin, the iron storage protein, should be above 40 to 60 ng/mL for optimal energy and hair health. A complete iron panel including ferritin, serum iron, TIBC, and hemoglobin gives a full picture. Do not let your doctor order just a hemoglobin test and tell you your iron is fine. Hemoglobin is the last thing to drop in iron deficiency, and by the time hemoglobin is low, you have been iron deficient for months.

When Testing Is Actually Valuable

Despite the limitations discussed above, blood testing plays a legitimate role in specific clinical scenarios. The first is early menopause workup. For women under 40 who stop having periods, an FSH above 40 IU/L on two separate occasions at least one month apart is part of the diagnostic criteria for primary ovarian insufficiency, along with estradiol below 20 pg/mL. AMH can provide supportive information in this context, though it is not diagnostic. The second scenario is treatment monitoring. Women on HRT who continue to have symptoms should have their estradiol level checked to determine whether the dose needs adjustment. Women on testosterone therapy should have their free and total testosterone levels monitored, along with SHBG, to avoid supraphysiological levels. Women on thyroid medication need regular TSH checks to ensure their dose is appropriate.

The third scenario is ruling out other causes. As discussed, TSH and prolactin testing can identify conditions that mimic menopause and are treatable with entirely different interventions. The fourth scenario is fertility planning for women in their late 30s and early 40s. AMH, along with FSH on day three of the cycle, provides information about remaining reproductive window. A 2024 study from the University of Exeter followed 1,420 women with AMH testing and found that an AMH below 0.2 ng/mL in a woman under 38 predicted menopause within five years with 80 percent accuracy. For women who still want children, that information is critical for decision-making about egg freezing or expedited family building.

The bottom line on menopause blood tests is this: do not let a single number define your hormonal reality. Your symptoms are real regardless of what any lab report says. Use blood tests as tools to clarify and guide, not as verdicts to accept passively. If you walk into your doctor’s office with the full picture, your cycle history, your symptoms, and your questions about specific tests, you will get better answers than if you let them run a standard panel and tell you everything is normal. For the complete picture on managing menopause symptoms and treatments, start with our menopause treatment homepage and explore the